Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs

Cancer Research

Volumn 73, Issue 2, 2013, Pages 1000-1010

  Trinh, Bon Q ^a   Ko, Song Yi ^a   Barengo, Nicolas ^a   Lin, Shiaw Yih ^a   Naora, Honami ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DLX4 PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); HOMEODOMAIN PROTEIN; KU ANTIGEN; PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DLX4 GENE; DNA RECOMBINATION; DNA REPAIR; DNA STRAND BREAKAGE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GENE; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TOP2A GENE;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA HELICASES; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HOMEODOMAIN PROTEINS; HUMANS; TRANSCRIPTION FACTORS;

EID: 84872535554     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3538     Document Type: Article

References (50)

1. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003;4: 712-20.
2. Kasparek TR, Humphrey TC. DNA double-strand break repair pathways, chromosomal rearrangements and cancer. Semin Cell Dev Biol 2011;22: 886-97.
3. Adachi N, Suzuki H, Iiizumi S, Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 2003;278: 35897-902.
4. Malik M, Nitiss JL. DNA repair functions that control sensitivity to topoisomerase II-targeting drugs. Eukaryot Cell 2004;3: 82-90.
5. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004;103: 4659-65.
6. Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage. Mol Cancer Ther 2006;5: 1405-14.
7. Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009;9: 327-37.
8. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9: 338-50.
9. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 1992;52: 4467-72.
10. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 1993; 90: 3231-5.
11. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008;105: 9053-8.
12. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, Takayama M, et al. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 2001;81: 172-7.
13. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101: 644-50.
14. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011;29: 859-67.
15. Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, et al. Predictive value of HER-2 and topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Eur J Cancer 2006;42: 2954-60.
16. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, et al. Topoisomerase II alpha amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results ofCALGB8541/150013. J Clin Oncol 2009;27: 3430-6.
17. Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A. The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev 2009; 35: 662-7.
18. Gehring WJ, Qian YQ, Billeter M, Furukubo-Tokunaga K, Schier AF, Resendez-Perez D, et al. Homeodomain-DNA recognition. Cell 1994;78: 211-23.
19. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2: 777-85.
20. Samuel S, Naora H. Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur J Cancer 2005;41: 2428-37.
21. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/ D716Cdx2+/- compound mutant mice. Nat Genet 2003;35: 323-30.
22. Ee HC, Erler T, Bhathal PS, Young GP, James RJ. Cdx-2 homeodomain protein expression in human and rat colorectal adenoma and carcinoma. Am J Pathol 1995;147: 586-92.
23. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007;67: 3036-42.
24. Sellar GC, Watt KP, Li L, Nelkin BD, Rabiasz GJ, Porteous DJ, et al. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer. Int J Oncol 2002;21: 929-33.
25. Panganiban G, Rubenstein JL. Developmental functions of the Distalless/ Dlx homeobox genes. Development 2002;129: 4371-86.
26. Fu SW, Schwartz A, Stevenson H, Pinzone JJ, Davenport GJ, Orenstein JM, et al. Correlation of expression of BP1, a homeobox gene, with estrogen receptor status in breast cancer. Breast Cancer Res 2003;5:R82-7.
27. Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related to Drosophila Distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol 2007; 170: 1594-1606.
28. Tomida S, Yanagisawa K, KoshikawaK, Yatabe Y, Mitsudomi T, Osada H, et al. Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene 2007;26: 4600-8.
29. Haga SB, Fu S, Karp JE, Ross DD, Williams DM, Hankins WD, et al. BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia 2000;14: 1867-75.
30. Trinh BQ, Barengo N, Naora H. Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-b cytostatic program and blocks the antiproliferative effect of TGF-b. Oncogene 2011;30: 2718-29.
31. Peng G, Yim EK, Dai H, Jackson AP, Burgt I, Pan MR, et al. BRIT1/ MCPH1 links chromatin remodelling to DNA damage response. Nat Cell Biol 2009;11: 865-72.
32. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347: 1999-2009.
33. Chase MB, Fu S, Haga SB, Davenport G, Stevenson H,Do K, et al. BP1, a homeodomain-containing isoform of DLX4, represses the betaglobin gene. Mol Cell Biol 2002;22: 2505-14.
34. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305: 1873-81.
35. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011;103: 264-72.
36. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010;12:R5.
37. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009;15: 68-74.
38. Errami A, Smider V, RathmellWK, He DM, Hendrickson EA, Zdzienicka MZ, et al. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Mol Cell Biol 1996;16: 1519-26.
39. Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol 2005;25: 1100-12.
40. Dubnau J, Struhl G. RNA recognition and translational regulation by a homeodomain protein. Nature 1996;379: 694-9.
41. Renouf B, Soret C, Saandi T, Delalande F, Martin E, Vanier M, et al. Cdx2 homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells. Nucleic Acids Res 2012;40: 3456-69.
42. Rubin E,WuX, Zhu T, Cheung JC, Chen H, Lorincz A, et al.A role for the HOXB7 homeodomain protein in DNA repair. Cancer Res 2007;67: 1527-35.
43. Roberts SA, Strande N, Burkhalter MD, Strom C, Havener JM, Hasty P, et al. Ku is a 50-dRP/AP lyase that excises nucleotide damage near broken ends. Nature 2010;464: 1214-7.
44. Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000;404: 510-4.
45. Ferguson DO, Sekiguchi JM, Chang S, Frank KM, Gao Y, DePinho RA, et al. The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc Natl Acad Sci U S A 2000;97: 6630-3.
46. Rothkamm K, Kühne M, Jeggo PA, Löbrich M. Radiation-induced genomic rearrangements formed by nonhomologous end-joining of DNA double-strand breaks. Cancer Res 2001;61: 3886-93.
47. Dafou D, Ramus SJ, Choi K, Grun B, Trott DA, Newbold RF, et al. Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. Int J Cancer 2009;124: 1037-44.
48. Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002;62: 2791-7.
49. Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res 2003;63: 1798-805.
50. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004;39: 288-97.